Finance

Beta
Lists
2359:HKG
WuXi AppTec Ord Shs H
HK$116.80
-3.71%
(-4.50) 1D
Jun 9, 4:08:11 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2359...
Open
HK$119.20
High
HK$119.20
Low
HK$111.20
Mkt. cap
323.28B
Avg. vol.
5.88M
Volume
14.74M
Dividend
1.87%
Quarterly dividend
HK$0.55
Ex-dividend date
May 29, 2026
P/E ratio
14.47
52-wk high
HK$148.00
52-wk low
HK$70.75
EPS
HK$8.07
No. of employees
34K
Open
HK$119.20
High
HK$119.20
Low
HK$111.20
Mkt. cap
323.28B
Avg. vol.
5.88M
Volume
14.74M
Dividend
1.87%
Quarterly dividend
HK$0.55
Ex-dividend date
May 29, 2026
P/E ratio
14.47
52-wk high
HK$148.00
52-wk low
HK$70.75
EPS
HK$8.07
No. of employees
34K
News stories
From sources across the web
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees33.8K
FoundedDec 1, 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn
Last report
Apr 27, 2026
Fiscal period
Q1 2026
EPS / Est. (CNY)
CN¥1.57 / CN¥1.07
+46.73%beat
Revenue / Est. (CNY)
12.44B / 10.75B
+15.70%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
11.14B
12.04B
10.97B
12.44B
Cost of goods sold
-
6.07B
4.91B
6.17B
Cost of revenue
-
6.07B
4.91B
6.17B
Research and development expenses
-
311.73M
236.94M
266.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
854.49M
853.67M
891.80M
Operating expense
-
1.38B
1.26B
1.22B
Total operating expenses
-
7.45B
6.17B
7.39B
Operating income
-
4.59B
4.80B
5.04B
Other non operating income
-
-470.36M
281.37M
-266.37M
EBT including unusual items
-
5.13B
6.75B
5.61B
EBT excluding unusual items
-
5.11B
6.95B
5.19B
Income tax expense
-
1.55B
1.09B
936.77M
Effective tax rate
-
30.19%
16.12%
16.71%
Other operating expenses
-
57.96M
25.84M
726.05K
Net income
-
3.51B
7.08B
4.65B
Net profit margin
-
29.18%
64.49%
37.40%
Earnings per share
1.02
1.24
1.42
1.57
Interest and investment income
-
1.21B
1.87B
439.82M
Interest expense
-
-226.71M
-
-30.95M
Net interest expenses
-
981.72M
1.87B
408.87M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
5.21B
5.61B
5.85B
Gain or loss from assets sale
-
-158.03M
218.40M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer